Zepbound: Injection for Sleep Apnea Treatment
By Brandon Peters, M.D.
Zepbound (tirzepatide) is a prescription drug used to treat obesity, diabetes, and obstructive sleep apnea. As it induces weight loss, this may improve crowding of the upper airway that may contribute to snoring and sleep apnea. Research suggests that it may be an effective tool in long-term management. Zepbound may have side effects, however, and careful consideration of the risks and benefits may inform its use.
Use of Zepbound
Zepbound is available via prescription only. One of the glucagon-like peptide-1 (GLP-1) receptor agonist medications, Zepbound is self-administered via a weekly injection. The 2.5 mg dose is started once weekly for 4 weeks. If tolerated, it may be increased by 2.5 mg monthly to a maximum dose of 15 mg via weekly injection. Due to the gradual increase, it will take 5 months to reach the maximum dose.
It may reduce excess body weight in adults who are overweight or obese (the latter defined as a body mass index, or BMI, above 30 kg/m2). It is also approved to treat moderate-to-severe obstructive sleep apnea (OSA)—with an apnea-hypopnea index (AHI) >15 events per hour—in adults with obesity. It is meant to be used in combination with a reduced-calorie diet and increased physical activity.
It is the first medication to be approved for the treatment of sleep apnea. The use of Zepbound to treat sleep apnea was approved by the U.S. Food and Drug Administration (FDA) on December 20, 2024. This approval was based on the results of the SURMOUNT-OSA trial, reported in the New England Journal of Medicine in June 2024. This pivotal trial showed that people on Zepbound for 1 year reduced, on average, their weight by 20% and their sleep apnea severity by 50.7%. This means that a lot of study subjects with moderate to severe sleep apnea were able to normalize their breathing, although sleep apnea persisted to a lesser degree in many.
How It Works
More research is needed to fully understand how these medications work. Generally, Zepbound selectively binds to and activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This may help to reduce appetite and caloric intake. As weight loss occurs, fat tissue that is deposited at the base of the tongue and along the upper airway may be reduced and this will gradually increase airflow. It may also reduce pressure on the lungs, increasing lung capacity and allowing more air movement. These changes may resolve snoring and sleep apnea.
Pros
It may address excessive weight, the most reversible and frequent root cause of sleep apnea in certain people.
It may reduce the severity of sleep apnea, allowing for other treatment options (i.e., oral appliance, Inspire placement) or the cessation of treatment if the condition resolves.
It may benefit weight-related medical conditions, including diabetes, hyperlipidemia, hypertension, fatty liver disease, and cardiovascular (i.e., heart attack, heart failure, heart arrhythmia) and cerebrovascular (i.e., stroke, dementia) disease.
Cons
Weight loss is gradual and benefit may not be derived for months or years into treatment.
It may reduce sleep apnea severity, but the condition may persist.
It may not resolve sleep apnea in people who have other anatomy or risk factors contributing to the condition.
It must be used long-term (lifelong) to maintain the reduced weight. If stopped, the excessive weight may come back.
It may be expensive and not covered by insurance.
It may be inaccessible due to demand and production/inventory issues.
Who Should Not Use Zepbound
Zepbound should not be used in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The signs of thyroid tumors include a mass in the neck, difficulty swallowing or breathing, and persistent hoarseness.
Anyone with a prior hypersensitivity reaction, such as anaphylaxis or angioedema, to the medication should also abstain from use.
Due to the delay of gastric emptying, Zepbound may reduce the efficacy of oral hormonal contraceptives for 4 weeks after initiating, or changing the dose of the medication, and barrier contraceptive (i.e., condom) use is recommended during this interval. Weight loss is not recommended during pregnancy. There are no data on its use during breastfeeding.
The medication should not be taken with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonists.
Side Effects
Common
The most common side effects relate to gastrointestinal complaints, and the adverse reactions (listed from most to least common) may include:
Nausea
Diarrhea
Vomiting
Constipation
Stomach pain
Upset stomach
Injection-site reactions
Fatigue
Hypersensitivity
Belching
Hair loss
GERD
Flatulence (farting)
Bloating
Dizziness
Hypotension (low blood pressure)
Severe
At the highest dose (15 mg), 3.1% of people report severe gastrointestinal issues. Vomiting may contribute to dehydration and volume depletion, potentially triggering acute kidney injury or failure. Gallstones (cholelithiasis or cholecystitis) affected 1.1% of people, compared to 1% of controls. Acute pancreatitis, which may be fatal, has rarely been observed with GLP-1 treatment.
Hypersensitivity to the medication, including anaphylaxis, has been noted in 0.1% of users.
As Zepbound lowers blood glucose levels, this can lead to hypoglycemia, especially when used with other medications to treat diabetes. It may also worsen diabetic retinopathy and caution is advised in this condition.
As it delays gastric emptying, there may be an increased risk of pulmonary aspiration in the context of surgery.
Suicidal thoughts or behaviors have been reported with other weight management products and monitoring for mood changes may be indicated.
When to Check With Your Healthcare Provider
If you are experiencing side effects, especially with the initiation of the medication or an increase in its dose, check in with the prescribing provider. It may be necessary to lower the dose or discontinue the use of Zepbound. Any medication changes should be made in consultation with your medical professional.
Summary
Zepbound may be an effective long-term treatment for moderate to severe obstructive sleep apnea in people with obesity. The side effects are generally tolerable, and the gradual loss of weight may provide other health benefits. Due to the slow effects, people should initiate treatment with continuous positive airway pressure (CPAP) therapy for immediate relief of the condition. The CPAP pressure settings may be gradually reduced and a repeat sleep study may be indicated once weight loss plateaus to evaluate whether the condition has resolved. Insurance coverage may vary, and cost and access issues are common barriers to treatment. If stopped, gradual weight gain is likely to occur. Those who use Zepbound in combination with a reduced-calorie diet, increased physical activity, and ongoing CPAP therapy will derive the greatest benefit from its use.